Key clinical point: Suboptimal RAAS inhibitor dosing in CKD and heart failure linked to increased major adverse cardiac event and mortality risk.
Major finding: Mortality and MACE rates were significantly higher in patients on suboptimal doses of renin-angiotensin-aldosterone system inhibitors.
Study details: Observational study in 100,572 people with nondialysis chronic kidney disease and 13,113 with new-onset heart failure.
Disclosures: The study was funded by AstraZeneca. One author was an employee and stockholder of AstraZeneca, and five authors declared funding and support from the pharmaceutical sector, including AstraZeneca.
Linde C et al. J Am Heart Assoc. 2019 Nov 12. doi: 10.1161/JAHA.119.012655.